Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Cogent Biosciences (COGT) Leases (2019 - 2026)

Cogent Biosciences' Leases history spans 8 years, with the latest figure at $17.5 million for Q1 2026.

  • Quarterly Leases fell 10.46% to $17.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Mar 2026, down 10.46% year-over-year, with the annual reading at $18.1 million for FY2025, 10.05% down from the prior year.
  • Leases came in at $17.5 million for Q1 2026, down from $18.1 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $26.9 million in Q2 2022 to a low of $3.2 million in Q1 2022.
  • The 5-year median for Leases is $21.1 million (2024), against an average of $20.2 million.
  • The largest YoY upside for Leases was 741.43% in 2022 against a maximum downside of 23.31% in 2022.
  • Cogent Biosciences' Leases stood at $23.3 million in 2022, then decreased by 5.65% to $22.0 million in 2023, then dropped by 8.64% to $20.1 million in 2024, then dropped by 10.05% to $18.1 million in 2025, then decreased by 2.93% to $17.5 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Leases are $17.5 million (Q1 2026), $18.1 million (Q4 2025), and $18.6 million (Q3 2025).